Sequence Variations of Genes in the Estrogen Pathway & Perinatal

Status Active, not recruiting

Clinical Trial Summary

To elucidate the disease pathway of perinatal depression by identifying genetic variants which could play a role in predisposing to the condition and/or lead to better understanding of the pathogenesis of the condition. This is achieved by investigating for associations between oestrogen receptor genetic variants and perinatal depression.

Clinical Trial Description

Perinatal (antenatal and postnatal) depression is a common complication of childbearing, affecting 10 to 20% of mothers. In general, women are exposed to fluctuations in estrogen level during childbearing years, especially during pregnancy and following childbirth. For a subgroup of women with genetic predisposition rendering them more sensitive to such changes, pregnancy or childbirth can act as a trigger for the onset of perinatal depression. A case control study will be conducted to evaluate the association of variants in estrogen receptor and related genes with the disorder in our population. Women attending antenatal and postnatal clinics will be screened with the Edinburgh Postnatal Depression Scale and cases will be identified. DNA from controls who are well throughout the antenatal and postpartum period and cases meeting DSM IV criteria for depressive disorder will be genotyped for various genetic variants. The distribution of single nucleotide polymorphisms and haplotypes and non-genetic risk factors will be compared between cases and controls and within the case group. The risk factors for postnatal depression in relation to peripartum factors such as demographic, obstetric, anaesthetic and pain outcomes will be investigated. As perinatal depression is known to contribute to inadequate self-care and poor compliance with prenatal care, early diagnosis and treatment interventions are critical for the health and well-being of both mother and infant. In the short term, identified genetic markers that increase vulnerability to puerperal triggering of depression can be an additional screening tool to identify at-risk expectant mothers for early management during a very critical period for mother, infant, and family. In the long run, it may lead to identification of new pathways or treatment targets for this common but under-studied disorder. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02373709
Study type	Observational
Source	KK Women's and Children's Hospital
Contact
Status	Active, not recruiting
Phase
Start date	October 2010
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04746794` - Early Detection of GEnetic Risk (EDGE)	N/A
Completed	`NCT03792685` - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention	N/A
Recruiting	`NCT04970056` - Pancreatic Cancer Early Detection Consortium
Terminated	`NCT04119596` - Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease
Recruiting	`NCT04141462` - EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer	N/A
Completed	`NCT02826330` - Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease
Recruiting	`NCT05929976` - InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
Not yet recruiting	`NCT04620278` - Genetic Investigation of Cancer Predisposition
Not yet recruiting	`NCT06089421` - Genetic Information Assistant in Telegenetics	N/A
Completed	`NCT05975489` - Genetics in the Effect of Caffeine on Fat Oxidation	N/A
Completed	`NCT03954652` - Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH"	N/A
Completed	`NCT04113239` - Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus
Enrolling by invitation	`NCT04373525` - Prospective Evaluation on Cognitive Function and Its Associated Genetic Vulnerability in Cannabis Users
Completed	`NCT03362099` - Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING)	Phase 4
Recruiting	`NCT05857670` - Psyco Quality of Life and Procreation BRCA1/2
Active, not recruiting	`NCT04774445` - Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes	N/A
Not yet recruiting	`NCT06377033` - Using the EHR to Advance Genomic Medicine Across a Diverse Health System	N/A
Recruiting	`NCT05759143` - Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing	N/A
Active, not recruiting	`NCT04920513` - Universal- Versus Guidelines-Directed Genetic Testing for Germline Pathogenic Variants Utilizing a Multi-Gene Panel for Inherited Cancers in Non-Western Society.
Active, not recruiting	`NCT04781205` - Genome Driven Primary Care Clinics - an RCT	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Sequence Variations of Genes in the Estrogen Pathway and Perinatal Depression

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms